Back to top
more

Masimo (MASI)

(Delayed Data from NSDQ)

$137.00 USD

137.00
611,099

+0.75 (0.55%)

Updated May 3, 2024 04:00 PM ET

After-Market: $137.00 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (150 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Baxter's (BAX) New Premix Drug Now Available in the U.S.

Baxter's (BAX) latest frozen premix formulation is expected to support patient safety, simplify medication preparation and boost operational efficiencies.

Here's Why You Should Retain Intuitive Surgical (ISRG) Stock Now

Investors continue to be optimistic about Intuitive Surgical (ISRG) owing to its strength in robotics.

HealthEquity (HQY) New Tie Up to Meet Clients' Healthcare Needs

HealthEquity's (HQY) latest collaboration is expected to enhance digital transformation with Microsoft Azure and build better experiences for customers and employees.

3 Reasons to Add Avanos (AVNS) Stock to Your Portfolio

Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.

Philips (PHG) Inks 7-Year Partnership With Northwell Health

Philips (PHG) announces that it has entered into a seven-year agreement with Northwell Health, one of the largest healthcare providers in the state of New York.

Masimo's (MASI) New FDA Clearance to Boost Patient Monitoring

Masimo's (MASI) receipt of the FDA's De Novo grant is expected to combat opioid overdoses by boosting patient monitoring.

Why Is Masimo (MASI) Up 0.2% Since Last Earnings Report?

Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why Investors Should Retain Cigna (CI) Stock Now

Cigna (CI) remains well-poised for growth on the back of continually growing premiums within its Cigna Healthcare unit. Solid cash-generating abilities also enable it to deploy capital.

Masimo (MASI) Unveils Freedom Smartwatch With Privacy Switch

Masimo's (MASI) newest wearable product seamlessly integrates continuous health tracking technology and breakthrough features.

Three Reasons to Add Masimo (MASI) Stock to Your Portfolio

Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.

HealthEquity (HQY) Beats on Q4 Earnings, Margins Rise

HealthEquity (HQY) witnesses solid growth in HSAs, alongside recording robust performances in all its segments, in the fourth quarter of fiscal 2023.

Masimo (MASI) Moves to Strong Buy: Rationale Behind the Upgrade

Masimo (MASI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Masimo (MASI) PVi Achieves Acceptable Fluid Response in Study

Masimo (MASI) PVi helps clinicians reliably predict fluid responsiveness in young neurosurgical patients.

Masimo (MASI) Q4 Earnings Surpass Estimates, Margins Down

Masimo's (MASI) robust product shipments and continued strength in its healthcare business drive its Q4 sales.

Masimo (MASI) Q4 Earnings and Revenues Beat Estimates

Masimo (MASI) delivered earnings and revenue surprises of 12.82% and 2.67%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain Masimo (MASI) Stock for Now

Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.

Analysts Estimate Masimo (MASI) to Report a Decline in Earnings: What to Look Out for

Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Masimo's (MASI) Patient Monitoring Devices Favored by New Study

Masimo's (MASI) patient monitoring devices continue to aid researchers in their assessment of different ventilatory strategies for brain oxygenation during thoracoscopic surgery.

Masimo (MASI) Expands Partnership with Philips for W1 Watch

Masimo (MASI) and Royal Philips to create an open ecosystem of medical information using Masimo W1 watch and the latter???s patient monitoring ecosystem to improve home-care.

Here's Why You Should Retain Masimo (MASI) Stock for Now

Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.

Masimo (MASI) Gets Favorable Ruling in Apple Watch Patent Suit

A U.S. Administrative Law Judge ruled that Apple watches infringe one of Masimo's (MASI) pulse oximeter patents. An import ban may follow for Apple watches.

UnitedHealth's (UNH) UnitedHealthcare Unit to Aid Q4 Earnings?

An increase in the number of people served in the commercial domestic business of UnitedHealth's (UNH) UnitedHealthcare segment is likely to boost fourth-quarter results.

UnitedHealth (UNH) to Post Q4 Earnings: What You Should Know

UnitedHealth Group's (UNH) fourth-quarter results are likely to reflect growing premiums, products and higher expenses.

Masimo's (MASI) SpHb During Elective CS Favored by New Study

Masimo's (MASI) SpHb is likely to indicate clinically acceptable accuracy of Hb measurement even at low Hb levels in patients undergoing CS with antepartum hemorrhage.

Debanjana Dey headshot

3 Beaten-Down MedTech Stocks Poised for a Turnaround in 2023

Here are some dirt-cheap MedTech value stocks - DYNT, INGN, AVNS - which are expected to provide long-term gains.